Aureka Biotechnologies raises $100M Series B

Aureka develops AI-powered digital biology platforms for discovering protein therapeutics and antibody treatments. The company announced a $100M Series B on August 10, 2026, from its base in Laguna Hills, US. Investors and valuation were not disclosed in Crunchbase's round record; Lounge adds them as they are reported. It has raised more than $100M in total venture funding.